Current concepts and perspectives of immunosuppression in organ transplantation

[1] Calmus Y(2002)Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients Liver Transplant 8 123-131

[2] Scheele JR(2002)CHIC 304 International liver study group improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial Liver Transplant 8 132-142

[3] Gonzalez-Pinto I(2003)Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study Am J Transplant Jun 3 722-730

[4] Jaurietta EJ(2004)Campath-1H in renal transplantation: the University of Wisconsin experience Surgery 136 754-760

[5] Klar E(2006)Lymphocyte alloresponses of Campath-1H-treated kidney transplant patients Transplantation 81 81-87

[6] Pageaux GP(2006)The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation Transpl Int 19 705-714

[7] Scudamore CH(2005)How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation? Nat Clin Pract Nephrol Dez 1 74-75

[8] Cuervas-Mons V(2006)Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation Transpl Int 19 885-895

[9] Metselaar HJ(2006)Alemtuzumab (Campath-1H): a systematic review in organ transplantation Transplantation 81 1361-1367

[10] Prestele H(1998)Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients Lancet 351 1701-1702

[1] Calmus Y(2002)Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients Liver Transplant 8 123-131

[2] Scheele JR(2002)CHIC 304 International liver study group improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial Liver Transplant 8 132-142

[3] Gonzalez-Pinto I(2003)Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study Am J Transplant Jun 3 722-730

[4] Jaurietta EJ(2004)Campath-1H in renal transplantation: the University of Wisconsin experience Surgery 136 754-760

[5] Klar E(2006)Lymphocyte alloresponses of Campath-1H-treated kidney transplant patients Transplantation 81 81-87

[6] Pageaux GP(2006)The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation Transpl Int 19 705-714

[7] Scudamore CH(2005)How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation? Nat Clin Pract Nephrol Dez 1 74-75

[8] Cuervas-Mons V(2006)Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation Transpl Int 19 885-895

[9] Metselaar HJ(2006)Alemtuzumab (Campath-1H): a systematic review in organ transplantation Transplantation 81 1361-1367

[10] Prestele H(1998)Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients Lancet 351 1701-1702